Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

UnitedHealth Group said 2025 revenue at Optum would be $10 billion less than previously estimated. Now the company is saying ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds. Based ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Compugen Ltd. (NASDAQ: CGEN) Q1 2025 Earnings Call Transcript May 19, 2025 Compugen Ltd. misses on earnings expectations.

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...

On Tuesday, Leerink Partners adjusted its stance on Johnson & Johnson (NYSE:JNJ) stock, downgrading it from Outperform to Market Perform. The firm also lowered its price target to $153 from the ...